Targeting GOT1 in PDAC: Ziprasidone-Induced Metabolic Reprog
2026-05-11
Targeting GOT1 in PDAC: Ziprasidone-Induced Metabolic Reprogramming
Study Background and Research Question
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a five-year survival rate of only 8% (source: paper). The lack of effective early biomarkers and the aggressive nature of PDAC drive an urgent need for innovative therapeutic approaches. Tumor cells rewire their metabolic pathways to sustain proliferation, with glutamine metabolism playing a central role in this adaptation. In PDAC, the cytosolic enzyme glutamate-oxaloacetate transaminase 1 (GOT1) facilitates the conversion of aspartate to oxaloacetate, sustaining redox balance and cell growth. Previous research has implicated the KRAS-regulated non-canonical glutamine pathway, mediated by GOT1, as essential for PDAC progression. The study by Yang et al. (2022) addresses whether pharmacological inhibition of GOT1 could disrupt PDAC metabolism and suppress tumor growth, and identifies ziprasidone—a molecule previously used as an antipsychotic—as a potential GOT1 inhibitor (source: paper).Key Innovation from the Reference Study
A major innovation of this work is the repurposing of ziprasidone as a selective, non-competitive inhibitor of GOT1. Unlike prior GOT1 inhibitors (e.g., aminooxyacetate, which lack selectivity or mechanistic clarity), ziprasidone's inhibitory action is characterized in detail and linked to downstream metabolic disruption in PDAC models. This study provides both in vitro and in vivo evidence that targeting GOT1 with this small molecule impairs glutamine metabolism, disturbs cellular redox homeostasis, and restricts tumor proliferation (source: paper).Methods and Experimental Design Insights
The authors employed a multidisciplinary approach combining enzymatic assays, metabolomics, cell proliferation analyses, and in vivo xenograft models:- Biochemical characterization: Ziprasidone's effect on GOT1 activity was quantified, establishing non-competitive inhibition kinetics.
- Cell-based assays: Human PDAC cell lines (e.g., SW1990) were treated with ziprasidone, with assessments of proliferation, apoptosis, and migration.
- Metabolic profiling: Changes in glutamine metabolism and redox balance were measured, including the NADPH/NADP+ ratio and ROS levels.
- Genetic perturbation: GOT1 knockdown experiments confirmed pathway specificity—cells with reduced GOT1 expression showed diminished sensitivity to ziprasidone's anti-proliferative effects.
- In vivo validation: Antitumor efficacy was validated in SW1990-derived xenograft mouse models, with tumor growth, histopathology, and immunohistochemistry endpoints (source: paper).
Protocol Parameters
- cell cycle analysis dye | 0.5–10 μg/mL | fixed cells, flow cytometry | DAPI (hydrochloride) enables robust discrimination of cell cycle phases in PDAC and other cell lines | workflow_recommendation
- chromosome staining reagent | 0.2–2 μg/mL | fixed tissue sections | High specificity for A-T rich DNA sequences facilitates chromosome visualization in histochemistry | product_spec
- minor groove DNA binding dye | 1–5 μg/mL | live and fixed cells | Enhanced sensitivity in DNA quantitation and apoptosis assays | workflow_recommendation
Core Findings and Why They Matter
The study demonstrates several pivotal findings:- GOT1 inhibition by ziprasidone: Ziprasidone directly inhibits GOT1 enzyme activity in a non-competitive fashion, blocking the conversion of aspartate to oxaloacetate (source: paper).
- Disruption of glutamine metabolism: Treated PDAC cells show reduced glutamine-derived aspartate and impaired entry of carbon/nitrogen into biosynthetic pathways, essential for tumor growth.
- Redox imbalance and apoptosis induction: As a consequence of GOT1 inhibition, NADPH/NADP+ ratios drop, leading to increased reactive oxygen species (ROS) and cell death.
- In vivo efficacy: In mouse models, ziprasidone significantly suppressed tumor growth without apparent toxicity to normal tissues (source: paper).
- Target specificity: Knockdown of GOT1 in PDAC cells reduced the anti-proliferative effect of ziprasidone, confirming the mechanistic axis.
Comparison with Existing Internal Articles
Several internal analyses contextualize the workflow and methodological aspects relevant to this study:- DAPI (hydrochloride): Reliable DNA Staining for Organoids underscores the importance of reproducible DNA visualization for cell cycle and apoptosis studies, which are critical for assessing anti-proliferative effects in cancer research. The workflow guidance here aligns with the approaches used in the reference paper for cell cycle analysis and apoptosis detection.
- DAPI (Hydrochloride): Strategic Insights for Translational DNA Analysis discusses DNA quantitation and cell cycle checkpoint analysis in oncology, providing recommendations for integrating minor groove DNA binding dyes in tumor microenvironment research. This is directly relevant to the PDAC context where precise cell cycle analysis underpins assessment of metabolic intervention outcomes.
- The workflow recommendations found in DAPI (hydrochloride): Reimagining DNA Visualization and T... bridge single-cell analytics and high-content screening, methodologies also employed in GOT1 inhibitor studies to track cell fate and proliferation.
Limitations and Transferability
Despite the promising mechanistic insights, several limitations warrant consideration:- Model specificity: The study is largely based on a single PDAC cell line and corresponding xenograft model. Broader validation across diverse PDAC subtypes and primary patient-derived cells is needed.
- Off-target effects: While ziprasidone’s anti-proliferative activity correlates with GOT1 inhibition, its established pharmacology as an antipsychotic raises the possibility of off-target interactions, especially in vivo.
- Clinical transferability: The metabolic dependencies and microenvironmental factors in human PDAC tumors may affect the efficacy and safety profile of GOT1 inhibition strategies. Further preclinical and early-phase clinical studies are necessary (source: paper).